Search Results - "Hockly, Emma"

Suberoylanilide Hydroxamic Acid, a Histone Deacetylase Inhibitor, Ameliorates Motor Deficits in a Mouse Model of Huntington's Disease by Hockly, Emma, Richon, Victoria M., Woodman, Benjamin, Smith, Donna L., Zhou, Xianbo, Rosa, Eddie, Sathasivam, Kirupa, Ghazi-Noori, Shabnam, Mahal, Amarbirpal, Philip A. S. Lowden, Steffan, Joan S., Marsh, J. Lawrence, Thompson, Leslie M., Lewis, Cathryn M., Marks, Paul A., Bates, Gillian P.

“…Huntington's disease (HD) is an inherited, progressive neurological disorder that is caused by a CAG/polyglutamine repeat expansion and for which there is no…”
Get full text

Environmental enrichment slows disease progression in R6/2 Huntington's disease mice by Hockly, Emma, Cordery, Patricia M., Woodman, Benjamin, Mahal, Amarbirpal, Van Dellen, Anton, Blakemore, Colin, Lewis, Cathryn M., Hannan, Anthony J., Bates, Gillian P.

“…Huntington's disease is a genetic disorder that causes motor dysfunction, personality changes, dementia, and premature death. There is currently no effective…”
Get full text

Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease by Benn, Caroline L., Landles, Christian, Li, He, Strand, Andrew D., Woodman, Ben, Sathasivam, Kirupa, Li, Shi-Hua, Ghazi-Noori, Shabnam, Hockly, Emma, Faruque, Syed M.N.N., Cha, Jang-Ho J., Sharpe, Paul T., Olson, James M., Li, Xiao-Jiang, Bates, Gillian P.

“…In postmortem Huntington's disease brains, mutant htt is present in both nuclear and cytoplasmic compartments. To dissect the impact of nuclear and…”
Get full text

Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease by Hockly, Emma, Tse, Jamie, Barker, Amy L., Moolman, Donna L., Beunard, Jean-Luc, Revington, Adrian P., Holt, Kim, Sunshine, Sunny, Moffitt, Hilary, Sathasivam, Kirupa, Woodman, Benjamin, Wanker, Erich E., Lowden, Philip A.S., Bates, Gillian P.

“…Huntington's disease (HD) is an inherited progressive neurological disorder for which there is no effective therapy. It is caused by a CAG/polyglutamine repeat…”
Get full text

Inhibition of Polyglutamine Aggregation in R6/2 HD Brain Slices—Complex Dose–Response Profiles by Smith, Donna L., Portier, Ruben, Woodman, Ben, Hockly, Emma, Mahal, Amarbirpal, Klunk, William E., Li, Xiao-Jiang, Wanker, Erich, Murray, Karl D., Bates, Gillian P.

“…Huntington's disease (HD) is a late onset neurodegenerative disorder caused by a CAG/polyglutamine (polyQ) repeat expansion. PolyQ aggregates can be detected…”
Get full text

The HdhQ150/Q150 knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes by Woodman, Ben, Butler, Rachel, Landles, Christian, Lupton, Michelle K, Tse, Jamie, Hockly, Emma, Moffitt, Hilary, Sathasivam, Kirupa, Bates, Gillian P

“…Abstract The identification of the Huntington's disease (HD) mutation as a CAG/polyglutamine repeat expansion enabled the generation of transgenic rodent…”
Get full text

The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes by Woodman, Ben, Butler, Rachel, Landles, Christian, Lupton, Michelle K, Tse, Jamie, Hockly, Emma, Moffitt, Hilary, Sathasivam, Kirupa, Bates, Gillian P

“…The identification of the Huntington's disease (HD) mutation as a CAG/polyglutamine repeat expansion enabled the generation of transgenic rodent models and…”
Get full text

Standardization and statistical approaches to therapeutic trials in the R6/2 mouse by Hockly, Emma, Woodman, Benjamin, Mahal, Amarbirpal, Lewis, Cathryn M, Bates, Gillian

“…The R6/2 mouse is the most widely used animal model of Huntington’s disease (HD), a genetic disorder causing movement disorders, personality changes, dementia,…”
Get full text

Minocycline and doxycycline are not beneficial in a model of Huntington's disease by Smith, Donna L., Woodman, Benjamin, Mahal, Amarbirpal, Sathasivam, Kirupa, Ghazi-Noori, Shabnam, Lowden, Philip A. S., Bates, Gillian P., Hockly, Emma

“…Huntington's Disease (HD) is an inherited neurological disorder causing movement impairment, personality changes, dementia, and premature death, for which…”
Get full text

Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? by Bates, Gillian P, Hockly, Emma

“…Research conducted over the past 10 years has uncovered molecular mechanisms that are likely to be important in the early stages of Huntington's disease…”
Get full text

Minocycline is protective in a mouse model of Huntington's disease by Hersch, Steven, Fink, Klaus, Vonsattel, Jean Paul, Friedlander, Robert M.

Get full text

Reply by Hockly, Emma, Beunard, Jean‐Luc, Lowden, Philip, Bates, Gillian P.

Get full text

Reply by Hockly, Emma, Beunard, Jean‐Luc, Lowden, Philip, Bates, Gillian P.

Get full text

Reply by Hockly, Emma, Beunard, Jean-Luc, Lowden, Philip, Bates, Gillian P.

Get full text

The Hdh Q150/Q150 knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes by Woodman, Ben, Butler, Rachel, Landles, Christian, Lupton, Michelle K., Tse, Jamie, Hockly, Emma, Moffitt, Hilary, Sathasivam, Kirupa, Bates, Gillian P.

“…The identification of the Huntington's disease (HD) mutation as a CAG/polyglutamine repeat expansion enabled the generation of transgenic rodent models and…”
Get full text

Plans for HDBase—a research community website for Huntington's Disease by Goodman, Nathan, McCormick, Kim, Goldowitz, Dan, Hockly, Emma, Johnson, Carl, Kristal, Bruce, MacDonald, Marcy, Truant, Ray, Beuzekom, Minka van

“…We are developing a community website, called HDBase, to support basic scientific research on Huntington's Disease (HD). The core of the site is…”
Get full text